News
DMAC
6.32
-3.22%
-0.21
H.C. Wainwright Keeps Their Buy Rating on Diamedica Therapeutics (DMAC)
TipRanks · 2d ago
DiaMedica outlines ReMEDy2 interim analysis by end of 2026 with potential 300-700 patient resample size
Seeking Alpha · 3d ago
DiaMedica Therapeutics reports Q1 EPS (19c), consensus (19c)
TipRanks · 3d ago
DiaMedica sees cash, equivalents funding operations through 2027
TipRanks · 3d ago
DiaMedica Therapeutics GAAP EPS of -$0.19 misses by $0.01
Seeking Alpha · 3d ago
DiaMedica Q1 net, operating income miss estimates; R&D costs to rise moderately
Reuters · 3d ago
DiaMedica Q1 FY26 net loss widens to $10 million
PUBT · 3d ago
DIAMEDICA THERAPEUTICS INC - REPORTS $51.3 MLN IN CASH AND INVESTMENTS, RUNWAY THROUGH 2027
Reuters · 3d ago
*Diamedica Therapeutics 1Q Loss/Shr 19c >DMAC
Dow Jones · 3d ago
Press Release: DiaMedica Therapeutics Reports -3-
Dow Jones · 3d ago
Press Release: DiaMedica Therapeutics Reports -2-
Dow Jones · 3d ago
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Barchart · 4d ago
DMAC's Preeclampsia Bet May Already Be Priced Into Eighteen-Cent Loss Estimate
Barchart · 5d ago
Weekly Report: what happened at DMAC last week (0427-0501)?
Weekly Report · 6d ago
DiaMedica Therapeutics updates financial calendar with upcoming quarterly results call
PUBT · 04/30 12:30
DIAMEDICA THERAPEUTICS TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE MAY 7, 2026
Reuters · 04/30 12:25
Weekly Report: what happened at DMAC last week (0420-0424)?
Weekly Report · 04/27 09:34
Weekly Report: what happened at DMAC last week (0413-0417)?
Weekly Report · 04/20 09:33
Weekly Report: what happened at DMAC last week (0406-0410)?
Weekly Report · 04/13 09:34
More
Webull provides a variety of real-time DMAC stock news. You can receive the latest news about Diamedica Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.